MedPath

Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy

Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Ovarian Sarcoma
Ovarian Stromal Cancer
Recurrent Endometrial Carcinoma
Recurrent Ovarian Epithelial Cancer
Recurrent Ovarian Germ Cell Tumor
Stage III Endometrial Carcinoma
Stage III Ovarian Epithelial Cancer
Stage III Ovarian Germ Cell Tumor
Stage IV Endometrial Carcinoma
Stage IV Ovarian Epithelial Cancer
Interventions
First Posted Date
2006-12-07
Last Posted Date
2014-06-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
38
Registration Number
NCT00408655
Locations
🇨🇦

National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 2
Terminated
Conditions
Peritoneal Cancer
Fallopian Tube Cancer
Stage 3 Cancer
Stage 4 Cancer
Ovarian Cancer
Interventions
First Posted Date
2006-12-06
Last Posted Date
2018-03-08
Lead Sponsor
UConn Health
Target Recruit Count
5
Registration Number
NCT00408070
Locations
🇺🇸

University of Connecticut Health Center, Farmington, Connecticut, United States

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Phase 1
Terminated
Conditions
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
First Posted Date
2006-12-05
Last Posted Date
2019-10-18
Lead Sponsor
Celgene
Target Recruit Count
6
Registration Number
NCT00407407
Locations
🇺🇸

University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2
Completed
Conditions
Melanoma (Skin)
Interventions
First Posted Date
2006-11-28
Last Posted Date
2018-10-16
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
76
Registration Number
NCT00404235
Locations
🇺🇸

BroMenn Regional Medical Center, Normal, Illinois, United States

🇺🇸

Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States

🇺🇸

Rush-Copley Cancer Care Center, Aurora, Illinois, United States

and more 148 locations

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

Phase 2
Terminated
Conditions
Lung Cancer
Interventions
Drug: Bevacizumab
Drug: Pemetrexed
Procedure: Radiotherapy
Other: Folic Acid
Other: vitamin B12
Drug: carboplatin
First Posted Date
2006-11-22
Last Posted Date
2021-11-09
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
5
Registration Number
NCT00402883
Locations
🇺🇸

Wellstar Cancer Research, Marietta, Georgia, United States

🇺🇸

Oncology Hematology Care, Cincinnati, Ohio, United States

🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

and more 4 locations

Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
Non-Small-Cell Lung Cancer
Interventions
First Posted Date
2006-11-22
Last Posted Date
2010-02-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
133
Registration Number
NCT00402051
Locations
🇩🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Phase 2
Completed
Conditions
Endometrial Cancer
First Posted Date
2006-11-20
Last Posted Date
2007-09-05
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
42
Registration Number
NCT00401635
Locations
🇮🇹

Ospedale Fatebenefratelli, U.O. di Oncologia, Benevento, BN, Italy

🇮🇹

Ospedale Pierantoni, Divisione di Oncologia Medica, Forli', FO, Italy

🇮🇹

Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy

and more 1 locations

G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients

Phase 1
Completed
Conditions
Small Cell Lung Cancer
First Posted Date
2006-11-20
Last Posted Date
2016-01-14
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
85
Registration Number
NCT00401609
Locations
🇮🇹

Ospedale San Martino, Genova, GE, Italy

🇮🇹

Divisione di Oncologia Medica, U.S.L.L. 13, Noale, VE, Italy

🇮🇹

Ospedale Umberto di Frosinone, Frosinone, FR, Italy

and more 18 locations

MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Interventions
First Posted Date
2006-11-20
Last Posted Date
2016-01-14
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
26
Registration Number
NCT00401674
Locations
🇮🇹

Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy

🇮🇹

Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy

🇮🇹

Università Cattolica del Sacro Cuore, Dipartimento di Oncologia, Campobasso, CB, Italy

and more 7 locations

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Phase 1
Withdrawn
Conditions
Drug/Agent Toxicity by Tissue/Organ
Cognitive/Functional Effects
Brain and Central Nervous System Tumors
Breast Cancer
Psychosocial Effects of Cancer and Its Treatment
Interventions
Drug: carboplatin
Biological: trastuzumab
Drug: methotrexate
Drug: sodium thiosulfate
First Posted Date
2006-11-09
Last Posted Date
2017-04-21
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT00397501
© Copyright 2025. All Rights Reserved by MedPath